$IOVA 🚀 Speculation is growing around a potential pharma partnership or M&A deal! With major pharma meetings in London and AstraZeneca's Cambridge headquarters nearby, investors are watching closely for possible developments. Could a major catalyst be coming? 📈🔥 Bullish!
$SRPT The Most under the radar thing happening at Sarepta is the PMO/Trim combo trial, target unknown but it is everything the PPMO was and more. It really could stand all the current DMD drugs obsolete. Even Elevidys.
Trump dumping his Nvidia stock a few weeks before this Chinese spy story dropped is the least shocking thing I’ve ever heard in my entire life.
Straight to jail.
@KobeissiLetter Bruh I just put in enormous money in this dip. Hopefully this passes, this is insane. Fired for sleeping with coworker? Come on this man is one of the faces of AI. Derailing over this is dumb.
"On behalf of the Board, I am delighted to welcome three such accomplished pharma industry executives to PDS Biotech," said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. Read more on their experience: https://t.co/hd1Jt6dg5v $PDSB
Well, he didn’t name his opponent until a few weeks before the election.
He refused to debate her.
He did a very limited amount, immediate hits, and she went on everything.
He’s had over a decade in office and has been absolutely nothing for Texans.
He celebrates companies coming to Texas, but doesn’t force them to hire American only while giving them taxpayer funded grants.
The list goes on and on.
He thought voters were going to come out just because this is a red state.
He never laid out solid policies.
He never gave voters a reason to go out and vote for him again.
$IOVA
Updated the financial projections in my model, I predict Q4 to be $IOVA's first FCF-positive quarter
1/4
$IOVA's cash burn is collapsing.
2026 ($M) | Q1 / Q2 / Q3
Operating CF: -72.1 / -60.8 / -4.5
Capex: 6.6 / 5.4 / 4.7
FCF: -78.7 / -66.3 / -9.2
2/4
Q4 FCF sensitivity ($M):
Revenue | 60% GM | 65% GM
$120M | -$10M | -$4M
$125M | -$7M | -$1M
$130M | -$4M | +$2M
$140M | +$2M | +$9M
3/4
ATM update: ~$89.7M of capacity remained entering Q3. $IOVA sold 8.67M shares at $10.34 average, raising $87.9M net. The 2025 ATM is now fully exhausted/terminated. $0 remains; no replacement ATM disclosed as of Nov 8.
4/4
If FCF turns sustainably positive, $IOVA may not need another raise. Could this mark the end of financing-driven dilution (Stock-based compensation aside)? The key risk is new, large clinical trials driving R&D spending significantly higher and potentially requiring additional capital.
@financialway We can also advertise that TIL brings hope to cancer sufferers worldwide. It is to become a Standard of Care and the world is yet to recognize this. Being at the forefront of this incredible science is worthy of a Nobel prize.